J Rheumatol:抗中性粒细胞胞浆抗体(ANCA)相关性血管炎中的肺受累

2017-08-11 xiangting MedSci原创

肺部受累很常见,140例接受胸部CT检查的AAV患者中,近80%患者胸部CT异常。

这项研究旨在描述由计算机断层扫描(CT)定义的抗中性粒细胞胞浆抗体(ANCA)相关性血管炎(AAV)在诊断时的肺受累。

纳入在三级转诊中心随访的起病后进行胸部CT扫描的AAV患者(n=140;75例女性;多血管炎肉芽肿,n = 79;微血管性血管炎MPA,n = 61)。使用预定义的方案从CT研究中评估肺部受累的影像学模式,并与蛋白酶3(PR3)-ANCA和髓过氧化物酶(MPO)-ANCA特异性进行比较。

77%的患者胸部CT检查异常。最常见的异常是结节性疾病(24%),其中大多数为支气管结节,其次为支气管扩张和胸腔积液(分别占19%),肺出血和淋巴结肿大(各为14%),肺气肿(13% )和空泡病变(11%)。PR3-ANCA阳性患者中心气道疾病和肺受累的结节型更为常见(p <0.05)。常规间质性肺炎(UIP)和支气管扩张在MPO-ANCA阳性患者中更为普遍(p <0.05)。MPO-ANCA阳性患者肺泡出血、胸腔积液、淋巴结肿大和肺静脉充血均更常见。

肺部受累很常见,140例接受胸部CT检查的AAV患者中,近80%患者胸部CT异常。中心气道疾病仅在PR3-ANCA阳性患者中发生,而UIP主要见于MPO-ANCA阳性患者。这些发现可能对AAV的调查、治疗和发病机制有重要影响。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1837316, encodeId=f4fa183e31690, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun May 20 00:52:00 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263170, encodeId=fad312631e0de, content=<a href='/topic/show?id=581e8968859' target=_blank style='color:#2F92EE;'>#血管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89688, encryptionId=581e8968859, topicName=血管炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Sun Aug 13 05:52:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296643, encodeId=30661296643ea, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Sun Aug 13 05:52:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400786, encodeId=77971400e8664, content=<a href='/topic/show?id=0ba9248543' target=_blank style='color:#2F92EE;'>#ANCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2485, encryptionId=0ba9248543, topicName=ANCA)], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/EE600EF84628E8BB8DF2285885814D26/100, createdBy=116f2265509, createdName=Boyinsh, createdTime=Sun Aug 13 05:52:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556291, encodeId=13621556291c4, content=<a href='/topic/show?id=8efc5515523' target=_blank style='color:#2F92EE;'>#抗中性粒细胞胞浆抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55155, encryptionId=8efc5515523, topicName=抗中性粒细胞胞浆抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57dd14737290, createdName=oliver174, createdTime=Sun Aug 13 05:52:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232531, encodeId=3dac23253198, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Aug 11 19:46:04 CST 2017, time=2017-08-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1837316, encodeId=f4fa183e31690, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun May 20 00:52:00 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263170, encodeId=fad312631e0de, content=<a href='/topic/show?id=581e8968859' target=_blank style='color:#2F92EE;'>#血管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89688, encryptionId=581e8968859, topicName=血管炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Sun Aug 13 05:52:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296643, encodeId=30661296643ea, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Sun Aug 13 05:52:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400786, encodeId=77971400e8664, content=<a href='/topic/show?id=0ba9248543' target=_blank style='color:#2F92EE;'>#ANCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2485, encryptionId=0ba9248543, topicName=ANCA)], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/EE600EF84628E8BB8DF2285885814D26/100, createdBy=116f2265509, createdName=Boyinsh, createdTime=Sun Aug 13 05:52:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556291, encodeId=13621556291c4, content=<a href='/topic/show?id=8efc5515523' target=_blank style='color:#2F92EE;'>#抗中性粒细胞胞浆抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55155, encryptionId=8efc5515523, topicName=抗中性粒细胞胞浆抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57dd14737290, createdName=oliver174, createdTime=Sun Aug 13 05:52:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232531, encodeId=3dac23253198, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Aug 11 19:46:04 CST 2017, time=2017-08-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1837316, encodeId=f4fa183e31690, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun May 20 00:52:00 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263170, encodeId=fad312631e0de, content=<a href='/topic/show?id=581e8968859' target=_blank style='color:#2F92EE;'>#血管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89688, encryptionId=581e8968859, topicName=血管炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Sun Aug 13 05:52:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296643, encodeId=30661296643ea, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Sun Aug 13 05:52:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400786, encodeId=77971400e8664, content=<a href='/topic/show?id=0ba9248543' target=_blank style='color:#2F92EE;'>#ANCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2485, encryptionId=0ba9248543, topicName=ANCA)], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/EE600EF84628E8BB8DF2285885814D26/100, createdBy=116f2265509, createdName=Boyinsh, createdTime=Sun Aug 13 05:52:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556291, encodeId=13621556291c4, content=<a href='/topic/show?id=8efc5515523' target=_blank style='color:#2F92EE;'>#抗中性粒细胞胞浆抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55155, encryptionId=8efc5515523, topicName=抗中性粒细胞胞浆抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57dd14737290, createdName=oliver174, createdTime=Sun Aug 13 05:52:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232531, encodeId=3dac23253198, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Aug 11 19:46:04 CST 2017, time=2017-08-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1837316, encodeId=f4fa183e31690, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun May 20 00:52:00 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263170, encodeId=fad312631e0de, content=<a href='/topic/show?id=581e8968859' target=_blank style='color:#2F92EE;'>#血管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89688, encryptionId=581e8968859, topicName=血管炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Sun Aug 13 05:52:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296643, encodeId=30661296643ea, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Sun Aug 13 05:52:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400786, encodeId=77971400e8664, content=<a href='/topic/show?id=0ba9248543' target=_blank style='color:#2F92EE;'>#ANCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2485, encryptionId=0ba9248543, topicName=ANCA)], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/EE600EF84628E8BB8DF2285885814D26/100, createdBy=116f2265509, createdName=Boyinsh, createdTime=Sun Aug 13 05:52:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556291, encodeId=13621556291c4, content=<a href='/topic/show?id=8efc5515523' target=_blank style='color:#2F92EE;'>#抗中性粒细胞胞浆抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55155, encryptionId=8efc5515523, topicName=抗中性粒细胞胞浆抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57dd14737290, createdName=oliver174, createdTime=Sun Aug 13 05:52:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232531, encodeId=3dac23253198, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Aug 11 19:46:04 CST 2017, time=2017-08-11, status=1, ipAttribution=)]
    2017-08-13 Boyinsh
  5. [GetPortalCommentsPageByObjectIdResponse(id=1837316, encodeId=f4fa183e31690, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun May 20 00:52:00 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263170, encodeId=fad312631e0de, content=<a href='/topic/show?id=581e8968859' target=_blank style='color:#2F92EE;'>#血管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89688, encryptionId=581e8968859, topicName=血管炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Sun Aug 13 05:52:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296643, encodeId=30661296643ea, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Sun Aug 13 05:52:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400786, encodeId=77971400e8664, content=<a href='/topic/show?id=0ba9248543' target=_blank style='color:#2F92EE;'>#ANCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2485, encryptionId=0ba9248543, topicName=ANCA)], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/EE600EF84628E8BB8DF2285885814D26/100, createdBy=116f2265509, createdName=Boyinsh, createdTime=Sun Aug 13 05:52:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556291, encodeId=13621556291c4, content=<a href='/topic/show?id=8efc5515523' target=_blank style='color:#2F92EE;'>#抗中性粒细胞胞浆抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55155, encryptionId=8efc5515523, topicName=抗中性粒细胞胞浆抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57dd14737290, createdName=oliver174, createdTime=Sun Aug 13 05:52:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232531, encodeId=3dac23253198, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Aug 11 19:46:04 CST 2017, time=2017-08-11, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1837316, encodeId=f4fa183e31690, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun May 20 00:52:00 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263170, encodeId=fad312631e0de, content=<a href='/topic/show?id=581e8968859' target=_blank style='color:#2F92EE;'>#血管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89688, encryptionId=581e8968859, topicName=血管炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Sun Aug 13 05:52:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296643, encodeId=30661296643ea, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Sun Aug 13 05:52:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400786, encodeId=77971400e8664, content=<a href='/topic/show?id=0ba9248543' target=_blank style='color:#2F92EE;'>#ANCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2485, encryptionId=0ba9248543, topicName=ANCA)], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/EE600EF84628E8BB8DF2285885814D26/100, createdBy=116f2265509, createdName=Boyinsh, createdTime=Sun Aug 13 05:52:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556291, encodeId=13621556291c4, content=<a href='/topic/show?id=8efc5515523' target=_blank style='color:#2F92EE;'>#抗中性粒细胞胞浆抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55155, encryptionId=8efc5515523, topicName=抗中性粒细胞胞浆抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57dd14737290, createdName=oliver174, createdTime=Sun Aug 13 05:52:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232531, encodeId=3dac23253198, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Aug 11 19:46:04 CST 2017, time=2017-08-11, status=1, ipAttribution=)]
    2017-08-11 131****1460

    学习了受益匪浅。

    0

相关资讯

J Rheumatol:ANCA相关性血管炎中的严重感染

与背景人群相比,AAV患者的严重感染率特别高,特别是年龄较大、肾功能受损的患者。

Nat Commun:治疗失明新策略!利用CRISPR阻止视网膜退化!

根据一项新的研究,在小鼠体内,沉默基因Nrl会阻止视网膜退行性疾病中的细胞丢失。这一发现可能导致人们开发出新的疗法来阻止视网膜色素变性等人类疾病中的视力丧失。这项研究是由来自美国国家眼科研究所(NEI)的研究人员开展的。相关研究结果于2017年3月14日在线发表在Nature C

ANN RHEUM DIS:ANCA相关性血管炎缓解期延长治疗研究

缓解后延长硫唑嘌呤/泼尼松龙维持治疗至诊断后24个月以上能够减少48个月内的复发风险,并改善AAV的肾功能。

Nat Commun:利用AAV测更**靶向肿瘤

近日,来自著名国际期刊nature communication在线发表了德国科学家一项最新研究成果,他们利用腺相关病毒靶向细胞表面受体,对细胞进行特异性基因修饰,并通过体内实验证明,这种方法可以实现对靶向细胞的精确制导,无脱靶效应。这项研究为特异性靶向细胞进行基因修饰提供了一种精确可行的方法。   研究人员发现靶向受体的腺相关病毒载体能够在体外和体内对罕见细胞类型进行基因修饰,实现精